An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA

Annals of the Rheumatic Diseases

Volumn 70, Issue 1, 2011, Pages 54-59

  Isenberg, D A ^a   Allen, E ^b   Farewell, V ^c   D'Cruz, D ^d   Alarcon G S ^e   Aranow, C ^f   Bruce I n , ^g   Dooley, M A ^h   Fortin, P R ⁱ   Ginzler, E M ^j   Gladman, D D ⁱ   Hanly, J G ^k   Inanc, M ^l   Kalunian, K ^m   Khamashta, M ^d   Merrill, J T ⁿ   Nived, O ^o   Petri, M ^p   Ramsey Goldman, R ^q   Sturfelt, G ^o   Urowitz, M ⁱ   Wallace, D J ^e   Gordon, C ^r   Rahman, A ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e Feinstein Institute of Medical Research ^*

^f Feinstein Institute of Medical Research   (United States)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ TORONTO WESTERN HOSPITAL   (Canada)

^j SUNY DOWNSTATE MEDICAL CENTER   (United States)

^k DALHOUSIE UNIVERSITY   (Canada)

^l ISTANBUL UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^o LUND UNIVERSITY HOSPITAL   (Sweden)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; ESTROGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ARTHRITIS; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; ESTROGEN THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS; LYMPHOCYTE DEPLETION; MEDICAL SPECIALIST; PHYSICIAN; PRIORITY JOURNAL; RHEUMATOLOGY; SCORING SYSTEM; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; UNITED KINGDOM;

EID: 78650632504     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.132068     Document Type: Article

References (18)

1. Favas C, Isenberg DA. B-cell-depletion therapy in SLE - what are the current prospects for its acceptance? Nat Rev Rheumatol 2009 ; 5 : 711-16.
2. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010 ; 62 : 222-33.
3. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35 : 630-40.
4. Bae SC, Koh HK, Chang DK, et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001 ; 10 : 405-9.
5. Gladman DD, Urowitz MB, Kagal A, et al. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000 ; 27 : 377-9.
6. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005 ; 142 : 953-62.
7. Buyon J, Kalunian KC, Urowitz MB, et al. Revision of the SELENA flare index. Arthritis Rheum 2009 ; 60 : S339.
8. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002 ; 29 : 288-91.
9. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993 ; 86 : 447-58.
10. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000 ; 9 : 651-4.
11. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005 ; 44 : 902-6.
12. Yee CS, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006 ; 54 : 3300-5.
13. Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007 ; 56 : 4113-19.
14. Yee SC, Farewell V, Isenberg DA, et al. The BILAG-2004 index is sensitive to change for assessment of SLE diseases activity. Rheumatology 2009 ; 48 : 491-5.
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25 : 1271-7.
16. Hochberg M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40 : 1725.
17. Isenberg D, Gordon C, Merrill J, et al. New therapies in systemic lupus erythematosus - trials, troubles and tribulations. working towards a solution. Lupus 2008 ; 17 : 967-70.
18. Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - a 5-yr prospective study. Rheumatology (Oxford) 2004 ; 43 : 1039-44.